HCS Pharma is selected for the co-innovation program France-Singapore 2022 of BPI France and Hello Tomorrow

We are very please to annonce our selection in the “CO-INNO INTERNATIONAL” program. Jointly organised by BPI France and Hello Tomorrow, the CO-INNO program accelerates and supports the most cutting-edge French startups from the discovery of the Singaporean ecosystem to the establishment of technological partnerships, funding and even their settlement Read more…

HCS Pharma awarded by an Innovation Award from NHRI during BioAsia in Taïwan

During the last BIO Asia-Taiwan event HCS Pharma was awarded by the National Health Research Institute (NHRI) as a key company (關鍵新創) in the “Partnering and Medical Innovation” category (攜手同行暨創醫獎) for the BIOMIMESYS® technology. BIOMIMESYS® was recognized as a groundbreaking technology, allowing to reproduce any type of healthy or cancerous Read more…